Traws Pharma (FRA:0T2) 3-Year Revenue Growth Rate : -18.10% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma 3-Year Revenue Growth Rate?

Traws Pharma's Revenue per Share for the three months ended in Dec. 2023 was €0.00.

During the past 3 years, the average Revenue per Share Growth Rate was -18.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -73.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was -73.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Traws Pharma was -18.10% per year. The lowest was -89.90% per year. And the median was -62.00% per year.

Competitive Comparison of Traws Pharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Traws Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Traws Pharma's 3-Year Revenue Growth Rate falls into.

Traws Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Traws Pharma (FRA:0T2) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Traws Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Traws Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma (FRA:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ONTX:USA

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines